MedTrace Logo

Expansion of a Dengue-1 Live Virus Human Challenge

NCT03869060 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-04-11

No results posted yet for this study

Summary

To evaluate the effectiveness of candidate dengue vaccine formulations, it is prudent to develop an appropriate challenge model. This study supports the expansion of the data set of the current Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) model to produce uncomplicated dengue-like illness.

Conditions

  • Dengue

Interventions

BIOLOGICAL

Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)

Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    collaborator INDUSTRY

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • State University of New York - Upstate Medical University

    lead OTHER

Principal Investigators

  • Stephen J Thomas, MD · State University of New York - Upstate Medical University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-11
Primary Completion
2019-09-20
Completion
2019-09-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03869060 on ClinicalTrials.gov